INTRODUCTION
Multiple myeloma (MM) accounts for up to 16,000 deaths per year, and 12,000 in the USA. 1 In the past 50 years, the combination of melphalan-prednisone (MP) has been the reference therapy for elderly MM patients. 2, 3 Recently, the combination of MP with thalidomide or bortezomib or lenalidomide has changed the treatment paradigm for elderly MM patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] In five independent randomized studies, the combination melphalan-prednisone-thalidomide (MPT) has significantly increased response rate and progression-free survival in comparison with MP. [4] [5] [6] [7] [8] [9] In a phase III study, the 4-drug combination bortezomib-melphalan-prednisone-thalidomide (VMPT) doubled the complete response (CR) rate in comparison with bortezomib-melphalanprednisone (VMP) alone. 10 Other agents may potentially enhance the therapeutic index of the MPT combination.
Defibrotide (DF) is a polydeoxyribonucleic acid derivative 13 which targets endothelial cell injury and is used for the treatment of various vascular disorders. 14, 15 In vitro data indicate that it may have anti-myeloma activity, especially in combination with other antineoplastic drugs, it markedly sensitizes MM cells to cytotoxic agents and overcomes resistance to chemotherapy. 16 MPT in patients with relapsed and relapsed/refractory MM, and to determine its safety and tolerability as part of this regimen.
DESIGN AND METHODS

Patients
From March through November 2006, 24 patients were enrolled. Inclusion criteria included relapsed or relapsed and refractory disease after at least 1 or 2 lines of therapy; measurable disease; platelet count ! 90 x 10 9 / L; absolute neutrophil count ! 1 x 10 9 / L; corrected serum calcium " 3.5 mmol/L; serum hepatic aminotransferase levels " 2.5-fold of upper limit of normal; total bilirubin " 1.5-fold of the ULN; and creatinine clearance ! 20 mL/min. Patients agreed to use contraception. The institutional review board at each participating center approved the study and all patients provided written informed consent.
Study design and Treatment
This was a phase I/II, multi-center, Occurrence of grade 4 hematologic toxicities (except neutropenia), grade 4 neutropenia ! 7 days or any ! grade 3 non-hematologic toxicities were defined dose limiting toxicity (DLT).
Efficacy and Safety
Efficacy assessments were performed after each induction cycle and every 6-8 weeks thereafter utilizing EBMT criteria and International Myeloma Working Group Criteria to assess VGPR. 20, 21 Toxicities were estimated weekly during the first three cycles, every 15 days during the last three cycles, and every 6-8 weeks during maintenance.
Progression-free survival was calculated from the time of enrollment to the date of progression, relapse, death or the patient was last seen in remission. Overall survival was estimated from the date of enrollment to the date of death or the date when the patient was last known to be alive. All adverse events were graded according to the National Cancer Institute
Common Toxicity Criteria (version 3.0).
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Endpoints and Statistical Analysis
The primary safety endpoints were to define DLT, which included febrile neutropenia, or grade 4 hematologic toxicities with neutropenia ! 7 days, or any grade 3 non-hematological toxicity in > 30% of patients during the first cycle of therapy. The maximum tolerated dose (MTD) was then defined as the dose level prior to that resulting in DLT. The primary efficacy 
© F e r r a t a S t o r t i F o u n d a t i o n
RESULTS
Patients' characteristics are showed in Table 1 heart disease plus interstitial pneumonia described above (1 patient).
Efficacy
In all patients, the overall response rate (ORR) was 52%, including PR 43% and CR plus VGPR 9 %; MR was reported in 22%, no response was reported in 22% and progressive disease in 4% of patients. In 90% of responding patients, PR occurred within the first 2 cycles, including 69% after the first cycle and 22% after the second. Median time from diagnosis was 52 months in all patients. The median duration of follow-up from study entry was 30 months (range 26-34). The 1-year progression-free survival was 34%, with a median of 10 months ( Fig. 2A) . From time of enrollment in the study, the 1 year overall survival among all patients was 90%, with a median of 29 months (Fig. 2B) . The median progressionfree survival was 17 months in patients who achieved CR and VGPR, and 11 months in those who achieved PR only.
Safety
No deaths were reported as a consequence of adverse events. The most frequent hematologic grade 3-4 toxicities were neutropenia (61%) and thrombocytopenia (39%). G-CSF support was required in 9 patients, rHuEPO support in 3 patients, concentrated red blood cells transfusion in 3 patients and platelets-transfusion in 2 patients. The most common non- somnolence, confusion, bradycardia, and pneumonia. Ataxia, motor neuropathy, and fatigue led to the discontinuation of thalidomide in one patient. DF was never discontinued, and was dose reduced in only one patient because of the grade 2 hematoma described above.
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DISCUSSION
In this phase I/II study, we evaluated dosing, safety and efficacy of the MPTD combination in advanced MM patients. The MTD of DF was defined as 7.2 g p.o. on days 1-4 followed by 4.8 g p.o. on days 5-35.
The combination of MPT was proven to be superior to MP in several independent randomized trials. [4] [5] [6] [7] [8] [9] MPT was also effective in relapsed/refractory patients. 25 The addition of bortezomib to the MP regimen has shown clear superiority to MP. 12 The 4-drug combination VMPT also leads to a significantly higher response rate in comparison with the 3-drug regimen VMP. 10, 26 However, toxicity and in particular DVT and PN are major limitations.
This provided the clinical rationale to investigate the consolidated MPT schema in combination with a fourth novel agent such as DF.
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In our study, CR plus VGPR was achieved in 9% of patients, with 52% PR or better.
Whilst the VGPR rate is lower than the 59% VGPR rate observed with the VMPT regimen, the median progression-free survival was 10 months for MPTD, with a comparable progression-free survival at 1-year of 61% in VMPT patients, 26 and a median progression-free survival of 9 months reported in a similar study evaluating bortezomib-melphalandexamethasone-thalidomide.
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The main goal of this study was not only to determine response rates, but also define the MTD of DF and reduce toxicity. In this regard, the low rate of DVT, absence of significant PN and clinical benefit seen with this combination are encouraging. Further phase II studies will now be needed to better define its efficacy in larger numbers of patients treated at the MTD. Severe myelosuppression was observed in 50% of patients, and infection occurred in 9% of patients. Neutropenia was the most common adverse event, with thrombocytopenia being less common. Other severe non-hematological side effects were rare, except grade 1/ 2 fatigue and hyperglycemia in 9% patients. These results compare favorably with two other studies of combinations including bortezomib, melphalan, thalidomide, and corticosteroids, where the incidence of infection was 7% and 15 % and significant PN developed in at least 6% and 10% of patients respectively. 24,26 Of note, Echart et al. suggested a potential role of DF for the prevention of DVT specifically induced by thalidomide. 19 In our study, no anti-thrombotic prophylaxis was administered and the incidence of DVT was only 4%. By comparison, despite the use of enoxaparin as the anticoagulant prophylaxis in MPT studies, DVT occurs in about 10% of patients. 8 These data therefore suggest a protective activity of DF against thrombotic events, and support future trials of DF in combination with thalidomide or other IMiDs, such as lenalidomide and pomalidomide. In conclusion, treatment with DF in combination with MPT showed a low incidence of severe adverse events. In the light of the capability of DF to modulate endothelial cell injury and thereby enhance sensitivity to chemotherapy, further studies are warranted to assess whether DF can augment MM cytotoxicity of melphalan, prednisone and thalidomide, while decreasing the risk of thrombosis. © F e r r a t a S t o r t i F o u n d a t i o n Figure 1A . Progression-free survival. Figure 1B . Overall survival.
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